Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,800 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, Chilamakuri CSR, Glont SE, Goode EA, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll JS. Nagarajan S, et al. Among authors: dunn s. Nat Genet. 2020 Mar;52(3):354. doi: 10.1038/s41588-020-0582-9. Nat Genet. 2020. PMID: 32005967
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
Nagarajan S, Rao SV, Sutton J, Cheeseman D, Dunn S, Papachristou EK, Prada JG, Couturier DL, Kumar S, Kishore K, Chilamakuri CSR, Glont SE, Archer Goode E, Brodie C, Guppy N, Natrajan R, Bruna A, Caldas C, Russell A, Siersbæk R, Yusa K, Chernukhin I, Carroll JS. Nagarajan S, et al. Among authors: dunn s. Nat Genet. 2020 Feb;52(2):187-197. doi: 10.1038/s41588-019-0541-5. Epub 2020 Jan 6. Nat Genet. 2020. PMID: 31913353 Free PMC article.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K. Dunn S, et al. Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14. Oncogene. 2022. PMID: 36241868 Free PMC article.
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.
Pfeifer M, Brammeld JS, Price S, Pilling J, Bhavsar D, Farcas A, Bateson J, Sundarrajan A, Miragaia RJ, Guan N, Arnold S, Tariq L, Grondine M, Talbot S, Guerriero ML, O'Neill DJ, Young J, Company C, Dunn S, Thorpe H, Martin MJ, Maratea K, Barrell D, Ahdesmaki M, Mettetal JT; Functional Genomics Centre; Brownell J, McDermott U. Pfeifer M, et al. Among authors: dunn s. Commun Biol. 2024 Apr 24;7(1):497. doi: 10.1038/s42003-024-06190-w. Commun Biol. 2024. PMID: 38658677 Free PMC article.
Long term health outcomes in people with diabetes 12 months after hospitalisation with COVID-19 in the UK: a prospective cohort study.
Gharibzadeh S, Routen A, Razieh C, Zaccardi F, Lawson C, Gillies C, Heller S, Davies M, Atkins H, Bain SC, Lone NL, Poinasamy K, Peto T, Robertson E, Young B, Johnston D, Quint J, Valabhji J, Ismail K, Marks M, Horsley A, Docherty A, Harrison E, Chalmers J, Ho LP, Raman B, Brightling C, Elneima O, Evans R, Greening N, Harris VC, Houchen-Wolloff L, Sereno M, Shikotra A, Singapuri A, Wain L, Langenberg C, Dennis J, Petrie J, Sattar N, Leavy O, Richardson M, Saunders RM, McArdle A, McASuley H, Yates T, Khunti K; PHOSP-COVID Study Collaborative Group. Gharibzadeh S, et al. EClinicalMedicine. 2024 Dec 27;79:103005. doi: 10.1016/j.eclinm.2024.103005. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39834716 Free PMC article.
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
Kong T, Laranjeira ABA, Letson CT, Yu L, Lin S, Fowles JS, Fisher DAC, Ng S, Yang W, He F, Youn M, Mark K, Jose AS, Liu J, Kim AB, Cox MJ, Fulbright MC, Jayanthan A, Los G, Rentschler SL, Ding L, Sakamoto KM, Dunn SE, Challen GA, Oh ST. Kong T, et al. Among authors: dunn se. Nat Commun. 2025 Jan 16;16(1):492. doi: 10.1038/s41467-024-55643-7. Nat Commun. 2025. PMID: 39820365 Free PMC article.
1,800 results